Displaying drugs 8351 - 8375 of 8495 in total
Amubarvimab
Amubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.
Investigational
ACR-16
ACR-16 is under investigation by NeuroSearch. ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington’s disease, Parkinson’s disease and schizophrenia respectively. ACR-16 is a dopamine stabilizer. ACR-16 is also being...
Investigational
Taribavirin
Investigational
alpha-Conotoxin VC 1.1
Investigational
Etazolate
EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.
Investigational
Dovitinib
Dovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with different cancers, including acute myeloid leukemia (AML) and multiple myeloma. Chiron currently has three ongoing Phase I...
Investigational
G4460
Investigational
Vasomera
Investigational
Caldaret
Investigational
XL228
XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation, survival and metastasis.
Investigational
Arylacenamide
Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.
Investigational
HLX70
HLX70, a recombinant humanized anti-S protein monoclonal antibody intended for intravenous infusion, was under investigation in clinical trials NCT05429385 and NCT04561076 to evaluate its safety and pharmacokinetics in healthy adult volunteers. The condition targeted by HLX70 in this study is COVID-19.
Investigational
ARQ 171
Investigational
Epothilone D
Investigational
XC221
XC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.
Investigational
AV-412
Investigational
ASI402
ASI402 is a monoclonal antibody that targets an aberrantly glycosylated antigen Mucin 1. It is being investigated in cancers.
Investigational
Annamycin
Investigational
FT516
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute...
Investigational
Fx-1006A
Fx-1006A is a small molecule compound with the potential to treat genetic disorders, such as familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP).
Investigational
Refametinib
Investigational
Tipapkinogene sovacivec
Investigational
Dociparstat sodium
Investigational
Displaying drugs 8351 - 8375 of 8495 in total